REG - Avacta Group PLC - Appointment of Nominated Adviser and Sole Broker

AvactaAnnouncement

11/06/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240611:nRSK8617Ra&default-theme=true

RNS Number : 8617R  Avacta Group PLC  11 June 2024

 

 

 

11 June 2024

 

Avacta Group plc

 

("Avacta" or the "Group" or the "Company")

 

Appointment of Nominated Adviser and Sole Broker

 

 

Avacta Group plc (AIM: AVCT), a life sciences company developing innovative,
targeted oncology drugs and powerful diagnostics, today announces the
appointment of Peel Hunt LLP as its Nominated Adviser and sole broker with
immediate effect.

 

 

-Ends-

 

 

 

For further information from Avacta Group plc, please contact:

 

 Avacta Group plc                                      Tel: +44 (0) 1904 21 7070

 Christina Coughlin, Chief Executive Officer           www.avacta.com (http://www.avacta.com)

 Tony Gardiner, Chief Financial Officer

 Michael Vinegrad, Group Communications Director

                                                       Tel: +44 (0) 207 418 8900

 Peel Hunt LLP (Nomad and Sole Broker)                 www.peelhunt.com (http://www.peelhunt.com)
 James Steel / Chris Golden / Patrick Birkholm

                                                       avacta@consilium-comms.com (mailto:avacta@consilium-comms.com)

 ICR Consilium (Media and IR)

 Mary-Jane Elliott / Jessica Hodgson / Sukaina Virji

 

About Avacta Group plc - https://www.avacta.com (https://www.avacta.com/)

 

Avacta Group is a UK-based life sciences company focused on improving
healthcare outcomes through targeted cancer treatments and diagnostics.

 

Avacta has two divisions: A clinical stage oncology biotech division
harnessing proprietary therapeutic platforms to develop novel, highly targeted
cancer drugs, and a diagnostics division focused on supporting healthcare
professionals.

 

Avacta has two proprietary platforms, pre|CISION™ and Affimer(®).

 

The pre|CISION™ platform is a highly specific substrate for fibroblast
activation protein (FAP) which is highly upregulated in most solid tumours
compared with healthy tissues. The pre|CISION(TM) platform harnesses this
tumour specific protease to activate pre|CISION(TM) peptide drug conjugates
and pre|CISION(TM) antibody drug conjugates in the tumour microenvironment,
reducing systemic exposure and toxicity, allowing dosing to be optimised to
deliver the best outcomes for patients.

 

The lead pre|CISION™ programme AVA6000, a peptide drug conjugate form of
doxorubicin, is in Phase 1 studies. It has shown a dramatic improvement in
safety and tolerability compared with standard doxorubicin and preliminary
signs of clinical activity.

 

Affimer(®) is a novel biologic platform which has significant technical and
commercial advantages compared with antibodies and can be used both to develop
advanced immunotherapies and to improve the performance of immunodiagnostics.

 

 

To register for news alerts by email go to
https://avacta.com/investors/investor-news-email-alerts/
(https://avacta.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPFLFLRRRIILIS